Article
Oncology
Flor Navarro, Noelia Casares, Celia Martin-Otal, Aritz Lasarte-Cia, Marta Gorraiz, Patricia Sarrion, Diana Llopiz, David Reparaz, Nerea Varo, Juan Roberto Rodriguez-Madoz, Felipe Prosper, Sandra Hervas-Stubbs, Teresa Lozano, Juan Jose Lasarte
Summary: The acidification of the tumor microenvironment inhibits the activity of antitumor T cells. Inhibiting the acid loader Ae2 enhances T cell function, while silencing Ae2 or overexpressing Hvcn1 improves the antitumor activity of T cells.
Article
Immunology
Ashi Mannan, Chirag Kakkar, Sonia Dhiman, Thakur Gurjeet Singh
Summary: The concept of using the patient's immune system to fight cancer has been around for some time, but recent progress has been significant. Immune checkpoint blockade and adaptive cell therapy (ACT) are two important approaches that have been approved for treating various types of tumors and have shown promising results.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Oncology
Sophia Stock, Anna-Kristina Kluever, Luisa Fertig, Vivien D. Menkhoff, Marion Subklewe, Stefan Endres, Sebastian Kobold
Summary: The clinical application of CAR T-cell therapy has revolutionized the treatment options for certain terminally ill patients with blood-borne cancers. However, the therapy can lead to severe toxicities, and efforts are being made to better control CAR T-cell activity and manage its associated side effects through various strategies and mechanisms.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Marion Mallet, Rasha E. Boulos, Vincent Alcazer, Paola Bonaventura, Yann Estornes, Nicolas Chuvin, Stephane Depil
Summary: This study compares the efficacy of cancer vaccines and Tg-T cell strategies in different tumor burdens. The study found that high doses of T cell infusion can achieve clinical efficacy, while therapeutic vaccines are more suitable for low or moderate tumor burdens.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Rihao Qu, Yuval Kluger, Junchen Yang, Jun Zhao, David A. Hafler, Diane S. Krause, Alexey Bersenev, Marcus Bosenberg, Michael Hurwitz, Liliana Lucca, Harriet M. Kluger
Summary: This study investigates the clonal cell expansion and persistence in adoptive cell therapy (ACT) using tumor infiltrating lymphocytes (TIL). The researchers performed single-cell RNA and T-Cell Receptor (TCR) sequencing on blood and tumor samples from a non-responsive ACT patient. They found varying clonal expansion during the preparation of the ACT product, with only one expanded clone preserved. The preserved clone persisted and remained activated for five months, while the contracted clones showed features of exhaustion and apoptosis. Analysis of additional ACT-treated patients and differentiation between viral- and tumor-specificity is recommended.
Article
Biochemistry & Molecular Biology
Ge Hui Tan, Carmen Chak-Lui Wong
Summary: Immune cell therapy has emerged as a common immunotherapy for cancer treatment. Understanding the biology and metabolism of immune cells is crucial for improving the efficacy of this therapy. Adoptive T cell therapy has shown effectiveness in limited types of cancer, and different types and generations of therapies have been developed.
ANTIOXIDANTS & REDOX SIGNALING
(2022)
Review
Immunology
Priyanka Maridhi Nanjireddy, Scott H. Olejniczak, Nataliya Prokopenko Buxbaum
Summary: Genetically engineered CAR T cells have the potential to cure refractory cancers. However, their effectiveness against solid tumors is limited by the immunosuppressive tumor microenvironment. This manuscript provides an overview of CAR T cell metabolism and discusses potential strategies to manipulate metabolic features for improved tumor responses.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
David Andreu-Sanz, Sebastian Kobold
Summary: While CD8(+) T cells have been the focus of most cancer immunotherapy approaches, increasing evidence indicates that CD4(+) T cells also play a crucial role in tumor elimination. These T cells can differentiate into different subsets, which have diverse effects on tumor progression depending on the cytokine milieu. This review provides an overview of the role of T helper subsets in the immune system, their implications in cancer immunology, and their applications in adoptive T-cell therapy.
Review
Immunology
Wendy Mao
Summary: The antitumor potential of personalized immunotherapy, including adoptive T-Cell therapy, has been shown in both preclinical and clinical studies. Combining cell therapy with targeted metabolic interventions can further enhance therapeutic outcomes. Research has found that metabolic reprogramming can increase T cell proliferation, survival, and anti-tumor cytotoxicity, improving the antitumor potential of T cell therapy and finding ways to improve the success rate of cell transplantation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Damie J. Juat, Stephanie J. Hachey, John Billimek, Michael P. Del Rosario, Edward L. Nelson, Christopher C. W. Hughes, Jason A. Zell
Summary: Colorectal cancer is the second leading cause of cancer-related deaths in the US. Adoptive T-cell therapy (ACT), leveraging the body's own immune system to recognize and target cancer, has gained popularity. This review summarizes the current data on the efficacy and safety of ACT in advanced CRC.
Review
Immunology
Yifan Xu, Jin Jiang, Yutong Wang, Wei Wang, Haokun Li, Wenyu Lai, Zhipeng Zhou, Wei Zhu, Zheng Xiang, Zhiming Wang, Zhe Zhu, Lingfeng Yu, Xiaolan Huang, Hua Zheng, Sha Wu
Summary: Gynecologic malignancies are leading causes of death among women worldwide, and adoptive T cell therapy using engineered T cells has shown promising efficacy in treating tumors. Ongoing research is driving the application of this therapy in the treatment of gynecologic malignancies.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Chen Chen, Zehua Wang, Yi Ding, Yanru Qin
Summary: Cellular metabolism plays a critical role in tumor cells and T cells. Dysregulated metabolism is a hallmark of cancer and impacts the function of T cells. The interaction between tumor and T cell metabolism can affect T cell responses. Metabolic competition in the tumor ecosystem suppresses effector T cells. Targeting metabolic reprogramming shows promise in cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Ella S. Atsavapranee, Margaret M. Billingsley, Michael J. Mitchell
Summary: Genetic engineering has transformed cancer immunotherapy by modifying primary T cells to enhance their therapeutic potential, with studies and clinical trials supporting the effectiveness of this approach.
Review
Immunology
Michael D. D. Claiborne
Summary: Utilizing the immune system's capacity to recognize and kill tumor cells has revolutionized cancer therapy. Recent studies on antitumor T cells suggest that long-lived memory or stem-like cells have superior tumor control compared to terminally differentiated effector cells. This Mini-Review explores the profiling of metabolic programs that generate and define subsets of memory T cells. It also discusses experimental approaches to enhance the durability and sustained antitumor response of memory T cells in the immunosuppressive tumor microenvironment, including overcoming hypoxia-induced changes in mitochondrial function, inhibitory effects of tumor metabolites, and regulation of T cell memory fate through glycogen metabolism.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Cell & Tissue Engineering
Faroogh Marofi, Safa Tahmasebi, Heshu Sulaiman Rahman, Denis Kaigorodov, Alexander Markov, Alexei Valerievich Yumashev, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Rebar N. Mohammed, Mostafa Jarahian, Roza Motavalli, Farhad Motavalli Khiavi
Summary: This passage discusses the challenges researchers face in curing cancer, particularly in the context of hematological cancers which are difficult to treat. It highlights the promising potential of CAR-T cell therapy, especially in targeting multiple myeloma, and emphasizes the need for further research and exploration in this area to improve treatment outcomes.
STEM CELL RESEARCH & THERAPY
(2021)
